001     136676
005     20240229105054.0
024 7 _ |a 10.1158/1055-9965.EPI-17-0744
|2 doi
024 7 _ |a pmid:29661801
|2 pmid
024 7 _ |a 1055-9965
|2 ISSN
024 7 _ |a 1538-7755
|2 ISSN
024 7 _ |a altmetric:38154307
|2 altmetric
037 _ _ |a DKFZ-2018-01144
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Cramer, Daniel W
|b 0
245 _ _ |a Anti-CA15.3 and Anti-CA125 Antibodies and Ovarian Cancer Risk: Results from the EPIC Cohort.
260 _ _ |a Philadelphia, Pa.
|c 2018
|b AACR
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1536310159_16664
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Background: Neoplastic and non-neoplastic events may raise levels of mucins, CA15.3, and CA125, and generate antibodies against them, but their impact on epithelial ovarian cancer (EOC) risk has not been fully defined.Methods: CA15.3, CA125, and IgG1 antibodies against them were measured in 806 women who developed EOC and 1,927 matched controls from the European Prospective Investigation of Nutrition and Cancer. Associations between epidemiologic factors and anti-mucin antibodies were evaluated using generalized linear models; EOC risks associated with anti-mucin antibodies, by themselves or in combination with respective antigens, were evaluated using conditional logistic regression.Results: In controls, lower antibodies against both mucins were associated with current smoking; and, in postmenopausal women, higher levels with longer oral contraceptive use and later-age-at and shorter-interval-since last birth. Lower anti-CA15.3 antibodies were associated with higher body mass and, in premenopausal women, more ovulatory cycles. Higher anti-CA15.3 and anti-CA125 antibodies were associated with higher risk for mucinous EOC occurring ≥ 3 years from enrollment. Long-term risk for serous EOC was reduced in women with low CA125 and high anti-CA125 antibodies relative to women with low concentrations of both.Conclusions: We found general support for the hypothesis that anti-mucin antibody levels correlate with risk factors for EOC. Antibodies alone or in combinations with their antigen may predict longer term risk of specific EOC types.Impact: Anti-CA125 and anti-CA15.3 antibodies alone or in perspective of antigens may be informative in the pathogenesis of EOC subtypes, but less useful for informing risk for all EOC. Cancer Epidemiol Biomarkers Prev; 27(7); 790-804. ©2018 AACR.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Fichorova, Raina N
|b 1
700 1 _ |a Terry, Kathryn L
|b 2
700 1 _ |a Yamamoto, Hidemi
|b 3
700 1 _ |a Vitonis, Allison F
|b 4
700 1 _ |a Ardanaz, Eva
|b 5
700 1 _ |a Aune, Dagfinn
|b 6
700 1 _ |a Boeing, Heiner
|b 7
700 1 _ |a Brändstedt, Jenny
|b 8
700 1 _ |a Boutron-Ruault, Marie-Christine
|0 0000-0002-5956-5693
|b 9
700 1 _ |a Chirlaque, Maria-Dolores
|b 10
700 1 _ |a Dorronsoro, Miren
|b 11
700 1 _ |a Dossus, Laure
|b 12
700 1 _ |a Duell, Eric J
|b 13
700 1 _ |a Gram, Inger T
|b 14
700 1 _ |a Gunter, Marc
|b 15
700 1 _ |a Hansen, Louise
|b 16
700 1 _ |a Idahl, Annika
|b 17
700 1 _ |a Johnson, Theron Scot
|0 P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa
|b 18
|u dkfz
700 1 _ |a Khaw, Kay-Tee
|b 19
700 1 _ |a Krogh, Vittorio
|b 20
700 1 _ |a Kvaskoff, Marina
|b 21
700 1 _ |a Mattiello, Amalia
|b 22
700 1 _ |a Matullo, Giuseppe
|b 23
700 1 _ |a Merritt, Melissa A
|b 24
700 1 _ |a Nodin, Björn
|b 25
700 1 _ |a Orfanos, Philippos
|b 26
700 1 _ |a Onland-Moret, N Charlotte
|b 27
700 1 _ |a Palli, Domenico
|b 28
700 1 _ |a Peppa, Eleni
|b 29
700 1 _ |a Quirós, J Ramón
|b 30
700 1 _ |a Sánchez-Perez, Maria-Jose
|b 31
700 1 _ |a Severi, Gianluca
|b 32
700 1 _ |a Tjønneland, Anne
|b 33
700 1 _ |a Travis, Ruth C
|b 34
700 1 _ |a Trichopoulou, Antonia
|b 35
700 1 _ |a Tumino, Rosario
|b 36
700 1 _ |a Weiderpass, Elisabete
|b 37
700 1 _ |a Turzanski-Fortner, Renée
|0 P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2
|b 38
|u dkfz
700 1 _ |a Kaaks, Rudolf
|0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
|b 39
|e Last author
|u dkfz
773 _ _ |a 10.1158/1055-9965.EPI-17-0744
|g Vol. 27, no. 7, p. 790 - 804
|0 PERI:(DE-600)2036781-8
|n 7
|p 790 - 804
|t Cancer epidemiology, biomarkers & prevention
|v 27
|y 2018
|x 1538-7755
909 C O |o oai:inrepo02.dkfz.de:136676
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 18
|6 P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 38
|6 P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 39
|6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|2 G:(DE-HGF)POF3-300
|v Cancer risk factors and prevention
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2018
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CANCER EPIDEM BIOMAR : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l Epidemiologie von Krebserkrankungen
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21